皓元医药: 上海皓元医药股份有限公司关于变更公司注册资本、修订《公司章程》并办理工商变更登记的公告

Group 1 - The company announced a change in registered capital and amendments to its Articles of Association, which will be submitted for shareholder approval [1][4] - As of August 27, 2025, the company’s registered capital increased by 10,479.00 CNY due to the conversion of "Haoyuan Convertible Bonds" into 10,479 shares [1] - The company completed the registration procedures for the first vesting period of the 2022 restricted stock incentive plan, resulting in an increase of 648,570 shares and registered capital by 648,570.00 CNY [2] - The company reduced its total share capital by 47,725 shares and registered capital by 47,725.00 CNY due to the cancellation of compensation shares related to performance commitments [3] - The company completed the registration for the second vesting period of the 2023 restricted stock incentive plan, increasing total share capital by 527,660 shares and registered capital by 527,660.00 CNY [4] - The total share capital changed from 210,959,781 shares to 212,098,765 shares, and registered capital changed from 210,959,781.00 CNY to 212,098,765.00 CNY [4] Group 2 - The company plans to amend its Articles of Association to reflect changes in registered capital and total share capital, in accordance with relevant laws and regulations [4] - The specific amendments to the Articles of Association include updates to the registered capital and total share capital clauses [4]